Twist Bioscience Analyst Ratings
Nurix Therapeutics Analyst Ratings
Intellia Therapeutics Analyst Ratings
Canaccord Genuity Maintains Buy on Intellia Therapeutics, Maintains $73 Price Target
Ionis Pharmaceuticals Analyst Ratings
CRISPR Therapeutics Analyst Ratings
Recursion Pharmaceuticals Analyst Ratings
Intellia Therapeutics Analyst Ratings
Intellia Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $26
Nurix Therapeutics Analyst Ratings
CRISPR Therapeutics Analyst Ratings
Ionis Pharmaceuticals Analyst Ratings
Twist Bioscience Analyst Ratings
Nurix Therapeutics Analyst Ratings
Twist Bioscience Analyst Ratings
Intellia Therapeutics Analyst Ratings
Guggenheim Initiates Twist Bioscience With Buy Rating, $53 Price Target
Ionis Pharmaceuticals Analyst Ratings
JMP Securities Remains a Hold on Intellia Therapeutics (NTLA)